According to Dan Clutter, Gentel’s Vice President of Commercial Development, “The SilverQuant name accurately describes our unique chromogenic detection technology as well as its application to protein quantitation. Further, SilverQuant is a strong trademark that adds a valuable intangible asset to the Company given its worldwide registration and existing prestige in the life sciences.”
The acquisition of the SilverQuant trademark complements other Gentel initiatives to grow its position as an industry-leading provider of multiplexed proteomics tools. This strategy includes the launch of highly innovative SilverQuant antibody array products and services, the most sensitive and easy-to-use antibody arrays available in the market; and SilverQuant pathogen arrays for animal health surveillance, a product line that enables exceptional diagnostic accuracy.
Gentel acquired the rights to array-based chromogenic detection technology from Eppendorf in 2008 for use in protein detection assay applications. The patented method uses gold particle-enhanced silver crystal deposition for detection and quantification of arrays. SilverQuant detection works with the Gentel Proteomics Multi-System™, a complete array platform that integrates chromogenic scanning and analysis of arrays at a price that is comparable to that of a bench-top ELISA system.
“We are extremely excited by the early response to SilverQuant detection technology, particularly by valuable market segments such like animal health and clinical diagnostics, where high sensitivity and affordability are crucial to workflow,” said Alex Vodenlich, Gentel President and CEO.